

Coeptis Therapeutics' Dave Mehalick on Making Cell Therapy Universally Accessible

written by InvestorNews | April 30, 2024

April 30, 2024 – In a recent interview with InvestorNews, Dave Mehalick, Chairman, President, and CEO of [Coeptis Therapeutics Holdings, Inc.](#) (NASDAQ: COEP), discussed the company's innovative approaches in cell therapy, highlighting their focus on making such treatments more universally accessible. Mehalick explained, "What we are working on is not failing, it's working. We've been able to create cells, not have to match those cells at all to the individual patient. Put those same cells in any patient and their body is accepting them and they are going to work." This strategy represents a shift from the traditional and costly autologous cell therapy to a more cost-effective allogeneic approach, potentially lowering the future cost of cell therapies and making them accessible to a broader population.

Furthermore, Coeptis Therapeutics has been actively forming partnerships with top academic institutions such as Duke University and the University of Pittsburgh. Mehalick shared details about their exclusive license agreement with the University of Pittsburgh, which now includes autoimmune indications for their SNAP-CAR T and SNAP-CAR NK cells. This expansion is significant as it allows the same cellular structures to be used not only against various cancers but also autoimmune diseases like lupus, potentially revolutionizing treatment paradigms across these conditions. He noted, "The beauty of SNAP-CAR is you could use the same cellular structure to attack not only a cancer, any type of cancer at any point on

the cancer, but we could use that same cellular structure to attack things like lupus.” This adaptability could lead to more cost-effective treatments and significantly impact patient care in oncology and autoimmune diseases alike.

To access the full interview, [click here](#)

Don't miss other InvestorNews interviews. Subscribe to the InvestorNews YouTube channel by [clicking here](#)

About Coeptis Therapeutics Holdings, Inc.

Coeptis Therapeutics Holdings, Inc., together with its subsidiaries including Coeptis Therapeutics, Inc. and Coeptis Pharmaceuticals, Inc., (collectively “Coeptis”), is a biopharmaceutical company developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases that have the potential to disrupt conventional treatment paradigms and improve patient outcomes. Coeptis' product portfolio and rights are highlighted by assets licensed from Deverra Therapeutics, including an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. Additionally, Coeptis is developing a universal, multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), and the GEAR cell therapy and companion diagnostic platforms, which Coeptis is developing with VyGen-Bio and leading medical researchers at the Karolinska Institutet. Coeptis' business model is designed around maximizing the value of its current product portfolio and rights through in-license agreements, out-license agreements and co-development relationships, as well as entering into strategic partnerships to expand its product rights and offerings, specifically those targeting cancer and infectious diseases. The

Company is headquartered in Wexford, PA.

To learn more about Coeptis Therapeutics Holdings, Inc., [click here](#)

Disclaimer: *Coeptis Therapeutics Holdings, Inc. is an advertorial member of InvestorNews Inc.*

This interview, which was produced by InvestorNews Inc. ("InvestorNews"), does not contain, nor does it purport to contain, a summary of all material information concerning the Company, including important disclosure and risk factors associated with the Company, its business and an investment in its securities. InvestorNews offers no representations or warranties that any of the information contained in this interview is accurate or complete.

This interview and any transcriptions or reproductions thereof (collectively, this "presentation") does not constitute, or form part of, any offer or invitation to sell or issue, or any solicitation of any offer to subscribe for or purchase any securities in the Company. The information in this presentation is provided for informational purposes only and may be subject to updating, completion or revision, and except as may be required by applicable securities laws, the Company disclaims any intent or obligation to update any information herein. This presentation may contain "forward-looking statements" within the meaning of applicable Canadian securities legislation. Forward-looking statements are based on the opinions and assumptions of the management of the Company as of the date made. They are inherently susceptible to uncertainty and other factors that could cause actual events/results to differ materially from these forward-looking statements. Additional risks and uncertainties, including those that the Company does not know about now or that it currently deems immaterial, may also

adversely affect the Company's business or any investment therein.

Any projections given are principally intended for use as objectives and are not intended, and should not be taken, as assurances that the projected results will be obtained by the Company. The assumptions used may not prove to be accurate and a potential decline in the Company's financial condition or results of operations may negatively impact the value of its securities. This presentation should not be considered as the giving of investment advice by the Company or any of its directors, officers, agents, employees or advisors. Each person to whom this presentation is made available must make its own independent assessment of the Company after making such investigations and taking such advice as may be deemed necessary. Prospective investors are urged to review the Company's profile on SedarPlus.ca and to carry out independent investigations in order to determine their interest in investing in the Company.